Dermatological Department, Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Department of Epidemiology and Health Statistics, School of Public Health, Guilin Medical University, No. 109 North Second Road, Huancheng, Qixing District, Guilin, 541001, Guangxi, China.
Arch Dermatol Res. 2019 Dec;311(10):801-805. doi: 10.1007/s00403-019-01967-0. Epub 2019 Aug 27.
The present study aimed to observe the therapeutic effect of combined mizolastine and proteoglycan in chronic urticaria. The patients were randomly divided into the treatment group (n = 56) and the control group (n = 44). The treatment group was medicated with calcium gluconate (10 mg/ time, 1 time/day), vitamin D3 (intramuscular 10 mg/time, 1 time/week), mizolastine (10 mg/time, 1 time/day), and proteoglycan (1.2 g/time, 3 times/day), while the control group was administered with the same drugs except proteoglycan for 4 weeks. After treatment with combined mizolastine and proteoglycan, therapeutic effect with symptoms decline index (SDI) more than 60% was significant different (44 vs. 24, p = 0.000973) and the relapse rate after 2 months was significantly lower (17.9% vs. 38.6%, p = 0.0202). Using ELISA, we found that the IFN-γ (37.88 ± 4.27 pg/mL vs. 21.91 ± 4.95 pg/mL, p = 0.028) levels were specifically increased in the experiment group. The combination of mizolastine plus proteoglycan is effective in treating chronic urticaria with better therapeutic effect and lower relapse rate through promoting IFN-γ production.
本研究旨在观察联合咪唑斯汀和蛋白聚糖治疗慢性荨麻疹的疗效。患者被随机分为治疗组（n=56）和对照组（n=44）。治疗组给予葡萄糖酸钙（10mg/次，1 次/天）、维生素 D3（肌内 10mg/次，每周 1 次）、咪唑斯汀（10mg/次，1 次/天）和蛋白聚糖（1.2g/次，3 次/天），对照组给予相同药物但不给予蛋白聚糖，疗程为 4 周。联合使用咪唑斯汀和蛋白聚糖后，症状缓解指数（SDI）大于 60%的治疗效果有显著差异（44 例 vs. 24 例，p=0.000973），且 2 个月后的复发率明显较低（17.9% vs. 38.6%，p=0.0202）。通过 ELISA 发现，实验组的 IFN-γ（37.88±4.27pg/mL 比 21.91±4.95pg/mL，p=0.028）水平显著升高。咪唑斯汀联合蛋白聚糖治疗慢性荨麻疹疗效确切，复发率低，可能通过促进 IFN-γ 的产生。
